Page 3 - Ben Comer News Today

From mixed topline results from a Phase 3 trial of lead candidate to the potential need to fund and conduct another trial prior to seeking regulatory...

From the looks of its modest open floor plan lab in Pittsburgh’s uptown, it might not be obvious to the casual observer that Imagine Pharma and...

Can Bayer’s “arm’s-length model” for acquired companies help turn the century-and-a-half year-old Big Pharma into a leader in...

Karuna Therapeutics’ late-stage drug for schizophrenia, if approved, could fund the company’s pipeline of next generation psychiatric...

Alnylam CEO Yvonne Greenstreet talks about what’s next for the company, including a transition into larger therapeutic areas and patient...

KemPharm’s experience in reworking product NDAs following FDA Complete Response Letters has created a unique capability within the company, and...

Albireo Pharma CEO Ron Cooper discusses the company’s three approaches to commercializing orphan drugs globally, and how to go from topline...

When CEO Avanish Vellanki founded and incorporated Rain Therapeutics on his living room couch in the spring of 2017, there was no drug in...

Three organizations pursuing three different strategies for new drug development have one thing in common: optimism about the future of treatments...

An outspoken champion of gender equity and diversity in the workplace, Arcellx CEO Rami Elghandour aims to put the company’s controllable CAR-T...